Comparative effects of LAMA-LABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD.
Triple therapy combinations of a long-acting muscarinic antagonist, a long-acting beta2-agonist and an inhaled corticosteroid (LAMA-LABA-ICS) for chronic obstructive pulmonary disease (COPD) were studied in randomized trials and observational studies, with variable results. We compared the effectiveness and safety of triple therapy to a LAMA-LABA combination in a real world clinical practice setting. We identified a cohort of COPD patients during 2002-2015, age 55 or older, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating LAMA-LABA-ICS were matched 4:1 on time-conditional propensity scores with patients initiating LAMA-LABA, followed for one year for the occurrence of a moderate or severe COPD exacerbation and severe pneumonia. The cohort included 6,921 initiators of LAMA-LABA-ICS matched to 1,932 initiators of LAMA-LABA. The adjusted hazard ratio (HR) of a COPD exacerbation associated with LAMA-LABA-ICS initiation compared with LAMA-LABA initiation was 0.97 (95% CI: 0.87-1.08). For patients with blood eosinophils >6%, the HR was 0.66 (95% CI: 0.46-0.94) and for patients with two or more prior exacerbations it was 0.83 (95% CI: 0.70-0.98). The incidence of severe pneumonia requiring hospitalization was increased with LAMA-LABA-ICS initiation (HR 1.46; 95% CI: 1.03-2.06). In a real world setting of COPD treatment, the triple combination of LAMA, LABA and ICS inhalers is generally as effective as combining LAMA and LABA inhalers in preventing COPD exacerbations. However, with the possible exception of patients with significant eosinophilia or frequent exacerbators, a LAMA-LABA combination without ICS may be preferable because it is associated with fewer severe pneumonias.